46OA Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate

Background: AVID100, an anti-EGFR-DM1 conjugate, showed potent activity in preclinical models in vitro and in vivo including in cell lines resistant to approved anti-EGFR mAbs.

http://ift.tt/2Ff7Qzd